Indication
Gaucher Disease Type 1
2 clinical trials
3 products
Clinical trial
A 4-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic, and Exploratory Efficacy of Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionStatus: Active (not recruiting), Estimated PCD: 2025-09-30
Product
VenglustatProduct
imigluceraseClinical trial
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory MedicationsStatus: Recruiting, Estimated PCD: 2025-07-31
Product
N-acetylcysteine